和誉-B(02256)：和誉医药于ESMO Asia 2025公布口服PD-L1抑制剂ABSK043联合 EGFR抑制剂伏美替尼治疗NSCLC的II期临床初步结果

8 12 月, 2025

One Min Read

10 Views

Last Update: 8 12 月, 2025

Written By

Other Articles

Previous

资本界金控(00204)股东将股票由中国银行(香港)转入香港上海汇丰银行转仓市值288.04万港元

Next

奥赛康(002755.SZ)：创新药利厄替尼片纳入国家医保目录

Related Posts

先消灭低价股！

1 Min Read

假期市场思考：A股还是美股？

1 Min Read

香港证券两日成交额破百亿！港股仍有市场？

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept